140 related articles for article (PubMed ID: 8693714)
21. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
[TBL] [Abstract][Full Text] [Related]
22. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M
J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572
[TBL] [Abstract][Full Text] [Related]
23. Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
Green MD
Pathol Biol (Paris); 1987 Jan; 35(1):49-53. PubMed ID: 3550612
[TBL] [Abstract][Full Text] [Related]
24. [Cardioxane in pediatric oncohematology].
Kurmashov VI; Gavrilova IE; Maiakova SA; Popa AV; Morozova OV; Ivanova LF; Kurdiukov BV; Gavrikova NV; Il'iashenko VV; Terzich M
Vopr Onkol; 1997; 43(4):456-9. PubMed ID: 9381705
[TBL] [Abstract][Full Text] [Related]
25. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma.
Elbl L; Vasova I; Tomaskova I; Jedlicka F; Navratil M; Pospisil Z; Vorlicek J
Neoplasma; 2006; 53(2):174-81. PubMed ID: 16575475
[TBL] [Abstract][Full Text] [Related]
26. [Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
Erlaky H; Tóth K; Szabolcs J; Horváth E; Kemény V; Müller J; Csóka M; Jókúti L; Erdélyi D; Kovács G
Magy Onkol; 2006; 50(1):25-32. PubMed ID: 16617380
[TBL] [Abstract][Full Text] [Related]
27. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
[TBL] [Abstract][Full Text] [Related]
28. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
29. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
31. [Echocardiographic assessment of circulation system in patients during and 3-5 years after all therapy in childhood].
Ostański M; Sońta-Jakimczyk D
Wiad Lek; 2002; 55(3-4):164-73. PubMed ID: 12182001
[TBL] [Abstract][Full Text] [Related]
32. [Dynamic stress echocardiography in asymptomatic patients treated for malignant diseases in childhood].
Elbl L; Hrstková H; Chaloupka V; Novotný J
Vnitr Lek; 2003 Apr; 49(4):273-9. PubMed ID: 12793049
[TBL] [Abstract][Full Text] [Related]
33. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin-induced cardiomyopathy.
Swain SM
N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049087
[No Abstract] [Full Text] [Related]
35. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
36. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
37. [Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
Gershanovich ML
Vopr Onkol; 2001; 47(1):119-22. PubMed ID: 11317530
[No Abstract] [Full Text] [Related]
38. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
39. [Diagnostic possibilities of late cardiotoxic sequelae of chemotherapy with anthracyclines].
Elbl L; Hrstková H; Chaloupka V; Novotný J
Vnitr Lek; 2002 Oct; 48(10):981-8. PubMed ID: 16737150
[TBL] [Abstract][Full Text] [Related]
40. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Sparano JA
Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
